Login to Your Account

Pique’s PT-107 extends median OS in phase II NSCLC trial

By Michael Fitzhugh
Staff Writer

Tuesday, November 7, 2017

An allogeneic whole cell vaccine for the treatment of NSCLC developed by Pique Therapeutics Inc. helped people with late-stage, second-line disease achieve a median overall survival of 12.5 months during a phase II trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription